Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Market Cap	14.80B
Revenue (ttm)	1.01B
Net Income (ttm)	520.90M
Shares Out	87.60M
EPS (ttm)	5.89
PE Ratio	28.68
Forward PE	29.04
Dividend	4.65 (2.75%)
Ex-Dividend Date	Apr 30, 2025

Volume	108,763
Average Volume	219,416
Open	171.00
Previous Close	170.50
Day's Range	168.50 - 171.00
52-Week Range	130.46 - 188.00
Beta	0.47
RSI	53.76
Earnings Date	Nov 12, 2025

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine (ADCV01), a drug candidate in Phase II clinical trials for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 94
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2024, TPEX:6712's revenue was 933.81 million, an increase of 23.13% compared to the previous year's 758.39 million. Earnings were 367.25 million, a decrease of -31.91%.